This technology includes isolates of the Dengue Virus (type 2) which can be used to develop diagnostic tests, antivirals and vaccinations. These isolates are from Puerto Rico DENV-2 and have complete whole genome sequencing completed. Additionally, these isolates represent current stains of Dengue Virus which are circulating in the Caribbean.
This technology includes clean, mycoplasma-free, rabies virus stocks for use in vaccine manufacturing. Rabies virus causes a nearly uniformly fatal disease, but can be prevented by timely vaccination. An inactivated rabies vaccine for human use was first prepared in cell culture in 1964, using the Pitman-Moore (PM) strain of fixed rabies virus. Typical rabies vaccine virus stocks stored at the Centers for Disease Control are heavily contaminated by mycoplasma, there this stock provides an alternative supply which is free of mycoplasma.
This technology includes a new concept to develop a bivalent IRV-IPV combination vaccine against rotavirus and polio using a dissolving microneedle patch. Specifically, we describe the formulation for IRV, the fabrication of a microneedle patch for combined IRV-IPV, and the proof of concept for assessing potential interference of immunogenicity and dose sparing in animal studies. Licensed oral rotavirus vaccines, while effective in developed and middle-income countries, are significantly less effective in reducing cases of severe diarrhea among children in developing countries.
This technology includes Escherichia coli isolate with MCR-1 gene which can be used in the development of diagnostic tests. The MCR-1 gene makes bacteria resistant to the antibiotic colistin, which is used as a last-resort drug to treat patients with multi-drug-resistant infections, including carbapenem-resistant Enterobacteriaceae (CRE). This gene exists on a plasmid, a small piece of DNA that is capable of moving from one bacterium to another, spreading antibiotic resistance among bacterial species.
The Ligand Epitope Antigen Presentation System (LEAPS) represents a breakthrough in immunotherapeutic technology developed by CEL-SCI Corporation. This technology employs a novel approach to boost the immune system's response to influenza, aiming to treat, manage, or even prevent the illness. By combining LEAPS with a specific peptide from the influenza virus, and administering it intravenously in mice, there's a marked improvement in the immune system's ability to fight off the virus.
The discovery outlined in the Employee Discovery and Invention Report represents a significant advancement in veterinary vaccine technology, specifically targeting the bovine respiratory syncytial virus (bRSV). This innovation involves a "DS2" version of the bRSV F vaccine, which has been engineered to enhance immunogenicity through a prefusion-stabilized form of the F protein, absent of the fusion peptide and reinforced by cavity-filling mutations and inter-protomer disulfides.
Norovirus is a leading cause of vomiting, diarrhea, and foodborne illness worldwide, with 700 million cases and 200,000 deaths occurring each year. Despite decades of work in the field, there are no preventive or therapeutic strategies specifically approved for even the most prevalent forms of human norovirus (i.e., GI, GII genogroups), which are highly contagious and carry an increased risk of severe complications in children, older adults, and those with immunocompromising conditions.
The described technology pertains to the development of bispecific antibodies targeting the Ebola virus glycoprotein. These antibodies, mAb114 and either S1-4-A09 or its engineered variant S1-4-A09 A80P, demonstrate specificity towards the Ebola virus (EBOV) glycoproteins from different strains, including Kikwit and Bundibugyo. The variant S1-4-A09 A80P retains binding specificity and activity but lacks a glycosylation motif, enhancing manufacturability without compromising function.